|Free Dividend Report|
|Stock Splits Calendar|
|HTBX Stock Split History|
|Preferred Stock Newsletter|
|HTBX Options Chain|
|Stock Message Boards|
HTBX (HTBX) has 2 splits in our HTBX split history database. The first split for HTBX took place on January 22, 2018. This was a 1 for 10 reverse split, meaning for each 10 shares of HTBX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split. HTBX's second split took place on December 11, 2020. This was a 1 for 7 reverse split, meaning for each 7 shares of HTBX owned pre-split, the shareholder now owned 1 share. For example, a 100 share position pre-split, became a 14.2857142857143 share position following the split.
When a company such as HTBX conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the HTBX split history from start to finish, an original position size of 1000 shares would have turned into 14.2857142857143 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into HTBX shares, starting with a $10,000 purchase of HTBX, presented on a split-history-adjusted basis factoring in the complete HTBX split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-47.24%|
|NightHawk Biosciences is a biopharmaceutical company focusing on the development and commercialization of therapies that arm the immune system against a range of diseases including cancer and infectious disease. Co.'s gp96 platform and RapidVax® platforms are designed to utilize the ability of gp96 to constitutively transport predefined antigens of interest to antigen presenting cells that in turn stimulate an antigen-specific immune response that includes B cells, CD4+ T-cells, and cytotoxic CD8+ T-cells. HS-110 (viagenpumatucel-L), an allogeneic therapy, is Co.'s main gp96 asset having completed Phase 2 enrollment of a non-small cell lung cancer clinical trial. According to our HTBX split history records, HTBX has had 2 splits.|
|HTBX Split History Table|
|01/22/2018||1 for 10|
|12/11/2020||1 for 7|
|Healthcare Stock Splits|
|HTBX is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: HTBX shares outstanding history